Relative tumor inhibitory and stimulatory activities of BCG vaccine preparations, lots and substrains in a quantitative mouse sarcoma bioassay.
A quantitative in vivo assay for BCG anticancer efficacy was developed to maximize detection of tumor-antagonistic mechanisms. Cultured S180 sarcoma cells admixed with various quantities of Mycobacterium bovis-BCG organisms were injected subcutaneously into CFW Swiss-Webster mice and response was measured as tumor incidence 14 days after injection. Assay of various BCG substrains, lots and killed preparations revealed characteristic patterns of BCG dose-dependent tumor inhibition and enhancement that suggest the existence in the vaccine of multiple active components, the relative concentrations of which vary among cultures. Inhibition of tumor growth by high doses of BCG (greater than 10 micrograms dry weight) was found to be a function of total cell mass and not of the bacterial viability, suggesting that this activity is dependent upon one or more heat-stable components.
Klegerman
M E
ME
Institute for Tuberculosis Research, College of Pharmacy, University of Illinois, Chicago 60607.
Zeunert
P L
PL
Lajeune
J
J
Lou
Y
Y
Groves
M J
MJ
D000818:Animals; D001500:BCG Vaccine / Q000737:chemistry / Q000494:pharmacology*; D004306:Dose-Response Relationship, Immunologic; D007167:Immunotherapy; D051379:Mice; D012510:Sarcoma 180 / Q000473:pathology / Q000628:therapy*
D001500:BCG Vaccine